Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)
The George Institute
Rabies
1 trial -
Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).
The George Institute
Rabies
1 trial -
Ramucirumab
Eli Lilly and Company
Urothelial Carcinoma
1 trial -
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
Sanofi-aventis Healthcare Pty Ltd
multiple sclerosis
1 trial -
Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors
Sanofi-aventis Healthcare Pty Ltd
Non-small cell lung cancer metastatic
1 trial -
Ranibizumab
Regeneron UK Limited
Macular Degeneration
2 trials -
Ranibizumab
Novartis Pharmaceuticals
Retinopathy of Prematurity (ROP)
1 trial -
Ranibizumab
Novartis Pharmaceuticals
Retinopathy of Prematurity
1 trial -
Ranibizumab
Hoffmann-La Roche
Neovascular Age-related Macular Degeneration (nAMD)
1 trial -
Ranibizumab 0.5 mg
Novartis Pharmaceuticals
Central Retinal Vein Occlusion
1 trial -
Ravulizumab
Regeneron UK Limited
Paroxysmal Nocturnal Hemoglobinuria
1 trial -
Ravulizumab
Alexion Europe SAS
Atypical Hemolytic Uremic Syndrome (aHUS)
2 trials -
Reslizumab
Teva Generics B.V
Eosinophilic Asthma
1 trial -
Reslizumab
Teva Pharma GmbH
Eosinophilic Asthma
5 trials -
Reslizumab
Teva Pharma GmbH
Severe Persistent Asthma
1 trial -
Retifanlimab (INCMGA00012), CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Bendatax 6 mg/ ml, Placebo liquid (not containing the active substance, otherwise identical to INCMGA0012)
Incyte
Squamous Carcinoma of the Anal Canal
1 trial -
Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 25 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 10 mg powder and solvent for solution for injection for paediatric use, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempi
The George Institute
juvenile idiopathic arthritis
1 trial -
Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa
Sanofi-aventis Healthcare Pty Ltd
Plasma cell myeloma
1 trial -
Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,
Sanofi-aventis Healthcare Pty Ltd
Cancer
1 trial -
Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib
Syndax Pharmaceuticals
Newly Diagnosed AML with an NPM1 mutation
1 trial -
Rilotumumab
Amgen
Gastric Cancer
1 trial -
Rilvegostomig, DS-8201a, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CARBOPLATIN, DOCETAXEL, PACLITAXEL
AstraZeneca AB
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
1 trial -
Rilvegostomig, TEGAFUR, GLUCOSE, INFLIXIMAB, CAPECITABINE, CISPLATIN, MYCOPHENOLATE MOFETIL, TEGAFUR, CAPECITABINE, GEMCITABINE, SODIUM CHLORIDE
AstraZeneca AB
Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)
1 trial -
Rilzabrutinib
Sanofi-aventis Healthcare Pty Ltd
immune thrombocytopenia (ITP)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources